Lauren Santye, Assistant Editor

Cytokine IL-36 found to drive some inflammatory processes while helping to resolve the inflammation in IBD patients.

Diabetes drug liraglutide may cause insulin-producing beta cells to deteriorate.

Military veteran tried to manage the symptoms of hepatitis C treatment before Harvoni cured him of the disease.

Early lineage T cells show promise in the treatment of acute lymphoblastic leukemia.

Interferon therapy not recommended for patients with minimal cancer in one lymph node.

Encapsulated rapamycin may lead to the delay of age-related disease and improve healthy aging.

Medicare Part D plans are increasingly creating smaller networks of pharmacies within larger networks that offer lower cost-sharing arrangements.

Anti-inflammatory phytochemical in green tea shows promise in blocking the effects of RA.

Tofacitinib citrate (Xeljanz) is the first and only once-daily oral Janus kinanse inhibitor for the treatment of moderate-to-severe RA.

Tofacitinib citrate (Xeljanz) is an extended-release tablet for patients with moderate-to-severe rheumatoid arthritis.

Proposal includes giving insurers the ability to withhold products from formularies if the cost of cancer drugs do not represent good value.

CRISPR/Cas9 gene editing platform able to remove Duchenne mutations in cells.

Study finds cancer patients need better support following treatment.

Research seeks to determine the genetic and environmental risk factors that trigger MS.

Formulary adjustments by the pharmacy benefit manager limited prescription drug spending jump to 5 percent.

Health care plans that improve the quality of care may see higher updates and enhance benefits for enrollees.

The cholesterol-lowering medications widely prescribed to reduce cardiovascular disease can also cause muscle toxicity.

Price inflation in non-specialty drug brands outweighed all other prescription medication trend drivers.

Dasatinib and demcizumab reduces lung adenocarcinomas and improves survival rates in lung cancer treatment.

Nanoparticle designed to directly hit tumors with a toxic cancerous drug without harming healthy tissue.

New HIV treatment approach scrambles DNA to stop it from multiplying.

Palbociclib (Ibrance) approved for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer.

Ibrance approved for the treatment of HR+, HER2- advanced or metastatic breast cancer.

Elamipretide treats rare genetic disorder that causes muscle weakness and severe fatigue.

Elamipretide targets the inner mitochondrial membrane and helps preserve mitochondrial energetics in patients with primary mitochondrial myopathy.

Antibody-drug conjugates and immunotherapy harness immune system to target breast cancer tumors.

Medicaid rebates for pantoprazole sodium (Protonix) alleged to have violated the Federal Civil False Claims Act.

Hysterectomies can reduce the risk for ovarian cancer but it can lead to surgical menopause.

Treatments approved for heart failure, cardiac arrhythmia, and infections offer epigenetic effects in cancer therapy.

Patient Action Plan can improve treatment across a variety of disease states in specialty pharmacy.